Papers
7
Total Citations
120
H-Index
4
About
Rachel Wooldridge is a radiation oncologist whose research has made meaningful strides in the treatment of early-stage breast cancer, with a particular focus on stereotactic partial breast irradiation (S-PBI) as an innovative alternative to conventional radiation approaches. Her most influential work centers on phase 1 dose-escalation clinical trials exploring both 5-fraction and single-fraction stereotactic body radiation therapy (SBRT) delivered via robotic stereotactic radiation systems following lumpectomy. Her 2017 paper on 5-fraction S-PBI has garnered 66 citations, establishing her as a pioneering voice in this evolving field. Wooldridge has extended her investigations into multi-institutional settings, broadening the generalizability of her findings, and has also examined cosmetic outcomes following S-PBI — a critical quality-of-life consideration for breast cancer patients. More recently, her pre-operative single-fraction ablative trial represents a bold frontier in minimizing treatment burden while maintaining oncologic efficacy. Across her body of work, Wooldridge consistently pushes toward shorter, more precise radiation regimens that preserve patient well-being, making her research highly relevant to clinicians and patients seeking effective, convenient treatment options for early-stage breast cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7